自身免疫病利妥昔单抗治疗中晚发性中性粒细胞减少的发生率、临床特征与结局
该单中心回顾性队列纳入738例接受利妥昔单抗诱导持续B细胞耗竭的成人自身免疫病患者,LON定义为B细胞耗竭期间不明原因中性粒细胞绝对值<1,000 cells/µl。B细胞耗竭1年累积发生率6.6%,系统性红斑狼疮和环磷酰胺联用独立增加风险,多数无症状且对非格司亭反应良好,但可伴严重感染。
要点
- B细胞耗竭1年LON累积发生率为6.6%(95%CI 5.0-8.7)
- SLE和环磷酰胺联用分别独立增加LON风险(aHR 2.96和1.98)
- LON多无症状(59.4%),但发热和脓毒症分别占31.3%和8.5%
核心结论
- LON是利妥昔单抗治疗自身免疫病常见且常为 incidental 的并发症,多数可逆且对非格司亭反应良好,但可伴严重感染,需警惕监测。
研究设计与样本
- 单中心回顾性队列研究,纳入738例接受利妥昔单抗诱导持续B细胞耗竭的成人自身免疫病患者。
主要发现
- 共71例患者发生107次LON,B细胞耗竭1年累积发生率为6.6%(95%CI 5.0-8.7)。
- 第一年发生率高于此后(7.2例/100人年[95%CI 5.4-9.6] vs 1.5例/100人年[95%CI 1.0-2.3])。
- SLE和环磷酰胺联用分别独立增加LON风险(校正HR 2.96[95%CI 1.10-8.01]和1.98[95%CI 1.06-3.71])。
- 微小病变肾病或局灶节段性肾小球硬化患者中未观察到LON。
- 59.4%的LON发作无症状,31.3%伴发热,8.5%伴脓毒症;69%的患者接受非格司亭治疗。
关键数值与推荐
- LON定义为B细胞耗竭期间不明原因中性粒细胞绝对值<1,000 cells/µl。
临床怎么用
- 对接受利妥昔单抗治疗的自身免疫病患者,尤其是SLE或联用环磷酰胺者,应警惕LON并监测中性粒细胞计数。
- 多数LON无症状且对非格司亭反应良好,但需注意发热和脓毒症等严重感染表现。
- 再次使用利妥昔单抗时需考虑LON复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Late-onset neutropenia (LON) is an underrecognized complication of rituximab treatment. We undertook this study to describe its incidence, risk factors, clinical features, management, and recurrence. METHODS: We conducted a single-center retrospective cohort study of 738 adult patients with autoimmune disease who were treated with rituximab to induce continuous B cell depletion. The primary outcome measure was LON, defined as an unexplained absolute neutrophil count of <1,000 cells/µl during B cell depletion. Secondary outcome measures included incidental diagnosis, fever, sepsis, filgrastim use, and recurrent LON. We assessed predictors of LON using Cox proportional hazards regression models. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated. RESULTS: We identified 107 episodes of LON in 71 patients. The cumulative incidence at 1 year of B cell depletion therapy was 6.6% (95% CI 5.0-8.7). The incidence rate during the first year was higher compared to thereafter (7.2 cases per 100 person-years [95% CI 5.4-9.6] versus 1.5 cases per 100 person-years [95% CI 1.0-2.3]). Systemic lupus erythematosus and combination therapy with cyclophosphamide were each independently associated with an increased risk of LON (adjusted HR 2.96 [95% CI 1.10-8.01] and 1.98 [95% CI 1.06-3.71], respectively). LON was not observed in minimal change disease or focal segmental glomerulosclerosis. The majority of episodes (59.4%) were asymptomatic. Fever and sepsis complicated 31.3% and 8.5% of episodes, respectively. Most patients (69%) were treated with filgrastim. Rituximab rechallenge occurred in 87% of patients, of whom 21% developed recurrent LON. CONCLUSION: LON is common and often incidental. Most cases are reversible and respond well to filgrastim. However, LON can be associated with serious infections and thus warrants vigilant monitoring.
引用
- Zonozi R, Wallace ZS, Laliberte K, et al. Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. Arthritis Rheumatol. 2020. PMID: 32892495. doi:10.1002/art.41501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。